GeneDx (NASDAQ:WGS) Price Target Increased to $19.00 by Analysts at BTIG Research

GeneDx (NASDAQ:WGS) had its price objective raised by equities research analysts at BTIG Research from $15.00 to $19.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential downside of 9.18% from the stock’s current price.

Separately, The Goldman Sachs Group boosted their price target on shares of GeneDx to $11.00 and gave the stock a “neutral” rating in a research note on Monday, April 15th.

GeneDx Stock Up 22.6 %

WGS opened at $20.92 on Tuesday. GeneDx has a one year low of $1.16 and a one year high of $21.49. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.10 and a quick ratio of 2.95. The firm has a market capitalization of $545.05 million, a P/E ratio of -4.04 and a beta of 2.75. The company has a fifty day moving average price of $9.63 and a 200-day moving average price of $5.19.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.01. GeneDx had a negative net margin of 60.86% and a negative return on equity of 34.40%. The company had revenue of $57.42 million during the quarter, compared to the consensus estimate of $57.00 million. Equities research analysts expect that GeneDx will post -2.02 earnings per share for the current fiscal year.

Insider Activity

In other GeneDx news, CEO Katherine Stueland sold 8,559 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $10.59, for a total value of $90,639.81. Following the sale, the chief executive officer now owns 66,698 shares in the company, valued at $706,331.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other GeneDx news, CEO Katherine Stueland sold 8,559 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $10.59, for a total value of $90,639.81. Following the sale, the chief executive officer now owns 66,698 shares in the company, valued at $706,331.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Casdin Capital, Llc acquired 40,000 shares of the business’s stock in a transaction on Monday, March 4th. The stock was acquired at an average price of $8.74 per share, for a total transaction of $349,600.00. Following the acquisition, the director now owns 2,702,609 shares of the company’s stock, valued at approximately $23,620,802.66. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 21,249 shares of company stock valued at $228,370. Insiders own 28.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in WGS. Trellus Management Company LLC lifted its stake in shares of GeneDx by 55.0% in the third quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after buying an additional 54,976 shares in the last quarter. Pathstone Family Office LLC raised its position in GeneDx by 262.2% in the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after acquiring an additional 39,327 shares during the period. HighTower Advisors LLC raised its position in GeneDx by 14.1% in the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock worth $865,000 after acquiring an additional 29,361 shares during the period. Oracle Investment Management Inc. raised its position in GeneDx by 14.9% in the third quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock worth $3,620,000 after acquiring an additional 128,731 shares during the period. Finally, Thompson Davis & CO. Inc. increased its stake in shares of GeneDx by 99.4% in the fourth quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock worth $55,000 after purchasing an additional 9,944 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.